

BETACARD

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only

Abbreviated Prescribing information for Betacard [Atenolol 25mg, 50mg and 100mg Tablet] [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Atenolol is a β 1-selective (cardioselective) beta-adrenergic receptor blocking agent without membrane stabilizing or intrinsic sympathomimetic (partial agonist) activities.

INDICATION: Betacard is indicated for the treatment of hypertension.

DOSAGE AND ADMINISTRATION: Dosage must be individualized. Dosages should be determined by individual titration, dosages may be increased gradually until optimum blood pressure achieved. Atenolol is usually given at a dosage of 25 to 100 mg per day.

CONTRAINDICATION: Contraindicated in patients with cardiogenic shock, uncontrolled heart failure, sick sinus syndrome, second-or third-degree heart block, untreated phaeochromocytoma, metabolic acidosis, bradycardia (<45 bpm), hypotension, severe peripheral arterial circulatory disturbances and hypersensitivity to the active ingredient.

WARNINGS & PRECAUTIONS: Cessation of therapy with atenolol patients with coronary artery disease, who are being treated with atenolol, should be advised against abrupt discontinuation of therapy. Use cautiously and stop the atenolol cardiac failure, without a history of cardiac failure (continued depression of the myocardium with β -blocking agents over a period of time), hepatic insufficiency, diabetes and hypoglycemia, bronchospastic diseases, thyrotoxicosis, untreated pheochromocytoma, concomitant use of calcium channel blockers, anesthesia and major surgery, pregnancy and fetal injury and impaired renal function.

DRUG INTERACTIONS: Catecholamine-depleting drugs (eg, reserpine), calcium channel blockers, disopyramide, amiodarone, prostaglandin synthase inhibiting drugs, eg. indomethacin and digitalis glycosides, concomitant use of insulin and oral antidiabetic drugs.

ADVERSE REACTIONS: Bradycardia, cold extremities, gastrointestinal disturbances, nausea, diarrhoea, fatigue, leg pain, lethargy, fever, combined with aching and sore throat, agranulocytosis, reversible mental depression progressing to catatonia, mesenteric arterial thrombosis, erythematous rash, thrombocytopenia, mood changes, nightmares, confusion, psychoses and hallucinations, depression, dreaming, dizziness, headache, paraesthesia, vertigo, light-headedness, drowsiness, dry eyes, visual disturbances, postural hypotension, intermittent claudication may be increased if already present, in susceptible patients raynaud's phenomenon, heart failure deterioration, precipitation of heart block, bronchospasm may occur in patients with bronchial asthma, dry mouth, hepatic toxicity including intrahepatic cholestasis, alopecia, psoriasis, exacerbation of psoriasis and impotence.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

IN/BETACARD 25,50,100 mg/AUG-2015/01/ABPI

(Additional information is available on request)